medRxiv
Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease
Preprint: non-randomised trial in peopleAlzheimer's disease
Papers by Randall J Bateman
39 results
- Alzheimer's & Dementia
Technology-natives and technology-adopters: Age differences in remote cognitive assessment in Alzheimer disease
Cohort study of 444 peopleAlzheimer's disease - Alzheimer's & Dementia
Remote digital cognitive assessment in a trial-ready Alzheimer's disease cohort: A scalable approach for early intervention studies
Cohort study of 123 peopleAlzheimer's disease
- AAIC 2025 Abstract
Age of plasma Aβ42/40 positivity in Black and White individuals
Study in peopleBiomarkers - AAIC 2025 Abstract
Interpreting positive plasma Aβ42/40 results when amyloid PET is negative
Study in peopleBiomarkers - AAIC 2025 Abstract
Baseline Participant Characteristics in the DIAN‐TU‐001 Trial
Trial in peoplePopulations - AAIC 2025 Abstract
DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience
Trial in peopleInterventions - AAIC 2025 Abstract
Exposure to TBI increases the susceptibility to tau phosphorylation at pT217
Study in peoplePopulations - AAIC 2025 Abstract
Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease
Study in peopleBiomarkers - AAIC 2025 Abstract
Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
Trial in peopleInterventions - AAIC 2025 Abstract
Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial
Trial in peopleInterventions - AAIC 2025 Abstract
Impact of genetic counseling and testing in individuals at high risk for Alzheimer ´s Disease from Latin America
Trial in peopleInterventions